ArticleFrontiers in endocrinology2026
A novel glucose-lipid metabolism-related indicator and its association with metabolic dysfunction-associated fatty liver disease: a cross-sectional study based on a health check-up population.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabolic dysfunction-associated fatty liver disease exacerbates hematoma expansion in intracerebral hemorrhage: an explainable machine learning approach.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the association between a novel glucose-lipid metabolic indicator, the cholesterol, high density lipoprotein, and glucose (CHG) index, and the prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD), as well as to evaluate its discriminative ability. Methods: This single-center cross-sectional study included 166,647 adults who underwent a health examination at the Health Management Center of the First Affiliated Hospital of Chongqing Medical University between July 2022 and March 2025. Multivariable logistic regression models were used to assess the association between the CHG index and the prevalence of MAFLD. Restricted cubic spline (RCS) functions were applied to explore potential nonlinear relationships. Receiver operating characteristic (ROC) curve analysis was used to compare the discriminative ability of the CHG index, triglyceride-glucose (TyG) index, and fatty liver index (FLI), and differences in AUCs were assessed using the DeLong test. Subgroup analyses were performed to assess its stability across different populations. Sensitivity analyses were performed to further examine the association between the CHG index and MAFLD. Results: A total of 166,647 participants were included, comprising 85,643 men (51.4%) and 81,004 women (48.6%), with an overall prevalence of MAFLD of 33.7%. The CHG index was significantly higher in participants with MAFLD than in those without (5.42 ± 0.34 vs. 5.05 ± 0.31; Conclusion: The CHG index was positively associated with MAFLD and showed good discriminatory ability in this large Chinese health check-up population. Although its performance was lower than that of the TyG index and FLI, it may still serve as a simple and accessible metabolic indicator for identifying individuals at higher risk of MAFLD in primary healthcare and health screening settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.